Gene Biotherapeutics (Gene Biotherapeutics) Additional Paid-In Capital : $115.55 Mil(As of Dec. 2020)

View and export this data going back to . Start your Free Trial

What is Gene Biotherapeutics Additional Paid-In Capital?

Gene Biotherapeutics's quarterly additional paid-in capital declined from Jun. 2020 ($115.55 Mil) to Sep. 2020 ($115.55 Mil) but then stayed the same from Sep. 2020 ($115.55 Mil) to Dec. 2020 ($115.55 Mil).

Gene Biotherapeutics's annual additional paid-in capital stayed the same from Dec. 2018 ($114.02 Mil) to Dec. 2019 ($114.02 Mil) but then increased from Dec. 2019 ($114.02 Mil) to Dec. 2020 ($115.55 Mil).

Gene Biotherapeutics Additional Paid-In Capital Historical Data

The historical data trend for Gene Biotherapeutics's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gene Biotherapeutics Additional Paid-In Capital Chart

Gene Biotherapeutics Annual Data

Trend

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Additional Paid-In Capital

Get a 7-Day Free Trial

113.71

113.94

114.02

115.55

Gene Biotherapeutics Quarterly Data
	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Dec17	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20
Additional Paid-In Capital	Get a 7-Day Free Trial															114.02	114.02	115.55	115.55	115.55

Gene Biotherapeutics Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

Gene Biotherapeutics Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Gene Biotherapeutics's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Gene Biotherapeutics (Gene Biotherapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Gene Biotherapeutics Inc (OTCPK:CRXM) » Definitions » Additional Paid-In Capital

Comparable Companies

Traded in Other Exchanges

N/A

Address

11230 Sorrento Valley Road, Suite 220, San Diego, CA, USA, 92121

Website

https://www.genebiotherapeutics.com

Gene Biotherapeutics Inc is a clinical stage biotechnology company focused on pre-clinical, clinical, and commercialization of angiogenic gene therapy biotherapeutics for strategic niche markets primarily for the treatment of cardiovascular disease. The company's lead product candidate Generx is an angiogenic gene therapy product candidate designed for medical revascularization for the potential treatment of patients with myocardial ischemia and refractory angina due to advanced coronary artery disease.

Executives

Andrew M Leitch	director	6615 CALLE PONTE BELLA, RANCHO SANTA FE CA 92091
Murray H Hutchison	director	C/O CADIZ INC., 550 SOUTH HOPE STREET, 2850, LOS ANGELES CA 90071
Dennis Mulroy	officer: Chief Financial Officer
Ronald I Simon	other: Former Director	485 MADISON AVENUE, 14TH FLOOR, NEW YORK NY 10022
Robert N Weingarten	director, officer: PRESIDENT and CFO	5439 LOCKHURST DRIVE, WOODLAND HILLS CA 91367

Gene Biotherapeutics (Gene Biotherapeutics) Headlines

From GuruFocus

Cardium Therapeutics Inc Reports Operating Results (10-Q)

By gurufocus 10qk • 11-09-2010

Cardium Therapeutics Inc Reports Operating Results (10-Q)

By gurufocus 10qk • 05-10-2010

Gene Biotherapeutics Announces Sale Of Excellagen Technology Platform; Retains Commercialization Rights For Greater China And Russian Federation

By PRNewswire PRNewswire • 09-05-2018

Baron Funds Comments on CarMax Inc.

By Holly LaFon • 02-06-2013